Denosumab biosimilar - Oncobiologics

Drug Profile

Denosumab biosimilar - Oncobiologics

Alternative Names: ONO4010; ONS-4010

Latest Information Update: 24 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oncobiologics
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bone cancer; Bone disorders; Bone metastases; Breast cancer; Male osteoporosis; Malignant hypercalcaemia; Multiple myeloma; Non-small cell lung cancer; Osteogenesis imperfecta; Osteoporosis; Postmenopausal osteoporosis; Rheumatoid arthritis

Most Recent Events

  • 14 Feb 2018 Oncobiologics plans clinical development of denosumab biosimilar in 2020
  • 24 Oct 2016 Denosumab is still in preclinical trials in USA (SC, Injection)
  • 24 Oct 2016 Oncobiologics plans a phase I trial in USA in 2017 (Oncobiologics Form S-1, June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top